A Hard Choice for Abbreviated Biologics License Applicants
February 4, 2019
By: Ted Mathias
Law360
Law360 published Axinn partner Ted Mathias' article, "A Hard Choice For Abbreviated Biologics License Applicants."
Click here to access the article. A subscription is required.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ITCTLA Mock Hearing Program 2025
Speaking Engagement
Intellectual Property
IBA Annual Conference 2025
Speaking Engagement
Antitrust
GCR Live: Global Merger Control 2025
Speaking Engagement
Antitrust
Thomson Reuters 24th Annual Law Firm COO & CFO Forum
Speaking Engagement
LegalNEXT 2025
Speaking Engagement
Antitrust
Informa Antitrust Texas 2025
Speaking Engagement
Antitrust
Why Some Retail Deals Get Deeper Scrutiny? An Examination of Retail Merger Review and Analysis
Podcast
Antitrust
Shifting Trends in Healthcare Antitrust Enforcement: Navigating the Evolving Landscape
Axinn Viewpoints
Antitrust
ACI Forum on Pharma & Biotech Patent Litigation USA 2025
Speaking Engagement
Intellectual Property
MCCA Gala 2025
Sponsorship
Antitrust